Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Breast cancer remains a leading cause of mortality in women, necessitating advanced therapeutic strategies.
• Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a novel class of drugs targeting tumors with specific genetic mutations, like BRCA1/2.
• The clinical utility of PARPis in monotherapy and combination treatments for breast cancer is an area of active research.

Purpose of the Study:

• To review the mechanism of action of PARP inhibitors (PARPis).
• To discuss the current clinical applications of PARPis in various breast cancer treatment settings, including neoadjuvant and adjuvant therapies.
• To explore the differences within the PARPis class and their clinical implications, as well as resistance mechanisms.

Main Methods:

• A systematic literature search of PubMed and ClinicalTrials.gov was conducted.
• The search terms used were "PARP inhibitors" and "breast cancer".
• The review includes published and ongoing clinical trials (Phase I-III).

Main Results:

• PARPis exploit synthetic lethality in BRCA1/2-mutated breast tumors.
• PARPis demonstrate potential in both monotherapy and combination strategies.
• The review details clinical applications, differences among PARPis, and resistance mechanisms.

Conclusions:

• PARP inhibitors are a significant advancement in breast cancer therapy, particularly for BRCA1/2-mutated tumors.
• Understanding PARPi mechanisms, clinical applications, and resistance is crucial for optimizing treatment outcomes.
• Further research into PARPi differences and resistance mechanisms will refine personalized breast cancer treatment.